Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib Assessment in Refractory Advanced Colorectal Cancer

NCT01929616 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT01929616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01929616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib Assessment in Refractory Advanced Colorectal Cancer
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
June 17, 2019
Enrollment
141 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced chemorefractory colorectal adenocarcinoma